Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

por Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Publicado 2013

Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

por Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Publicado 2013

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

por Engel, Samuel S, Golm, Gregory T, Shapiro, Deborah, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Publicado 2013

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

por Ommen, Elizabeth S., Xu, Lei, O’Neill, Edward A., Goldstein, Barry J., Kaufman, Keith D., Engel, Samuel S.
Publicado 2015

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

por Ommen, Elizabeth S., Xu, Lei, O’Neill, Edward A., Goldstein, Barry J., Kaufman, Keith D., Engel, Samuel S.
Publicado 2015

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency

por Raji, Annaswamy, Xu, Zhi Jin, Lam, Raymond L. H., O’Neill, Edward A., Kaufman, Keith D., Engel, Samuel S.
Publicado 2020

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2...

por Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado 2017

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

por Williams-Herman, Debora, Round, Elizabeth, Swern, Arlene S, Musser, Bret, Davies, Michael J, Stein, Peter P, Kaufman, Keith D, Amatruda, John M
Publicado 2008

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

por Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Publicado 2017

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoS...

por Scott, Russell, Morgan, Jerry, Zimmer, Zachary, Lam, Raymond L. H., O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Raji, Annaswamy
Publicado 2018

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin...

por Seino, Yutaka, Kaku, Kohei, Kadowaki, Takashi, Okamoto, Taro, Sato, Asako, Shirakawa, Masayoshi, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.
Publicado 2021

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin

por Kaku, Kohei, Kadowaki, Takashi, Seino, Yutaka, Okamoto, Taro, Shirakawa, Masayoshi, Sato, Asako, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.
Publicado 2021

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

por Meininger, Gary E., Scott, Russell, Alba, Maria, Shentu, Yue, Luo, Edmund, Amin, Himal, Davies, Michael J., Kaufman, Keith D., Goldstein, Barry J.
Publicado 2011

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

por Arjona Ferreira, Juan Camilo, Marre, Michel, Barzilai, Nir, Guo, Hua, Golm, Gregory T., Sisk, Christine McCrary, Kaufman, Keith D., Goldstein, Barry J.
Publicado 2013

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

por Mathieu, Chantal, Shankar, R. Ravi, Lorber, Daniel, Umpierrez, Guillermo, Wu, Fan, Xu, Lei, Golm, Gregory T., Latham, Melanie, Kaufman, Keith D., Engel, Samuel S.
Publicado 2015

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibito...

por Goldenberg, Ronald, Gantz, Ira, Andryuk, Paula J., O'Neill, Edward A., Kaufman, Keith D., Lai, Eseng, Wang, Yin Na, Suryawanshi, Shailaja, Engel, Samuel S.
Publicado 2017

Agency rescues competition for credit assignment among predictive cues from adverse learning conditions

por Kang, Mihwa, Reverte, Ingrid, Volz, Stephen, Kaufman, Keith, Fevola, Salvatore, Matarazzo, Anna, Alhazmi, Fahd H., Marquez, Inmaculada, Iordanova, Mihaela D., Esber, Guillem R.
Publicado 2021

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequ...

por Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O’Neill, Edward A., Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado 2017

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

por Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Publicado 2010

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus

por Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi
Publicado 2016